GAPDH and breast carcinoma: Our findings not only provide novel insights into DC-5163 as a promising GAPDH inhibitor for suppressing breast cancer but also indicate that PET/CT may be used as an effective noninvasive method for monitoring the efficacy of DC-5163 treatment (Fig. 6).